Abstract 1548P
Background
Currently, the U.S. is experiencing an ongoing shortage of carboplatin and cisplatin chemotherapy (platinum) first reported by the FDA on February 10, 2023, creating uncertainty for patients, oncologists, regulators, and biopharma. The real-world effects of this shortage on platinum prescribing and patient mortality have not been quantified.
Methods
This cohort study used Flatiron Health’s nationwide de-identified EHR-derived database. Included patients started first-line (1L) therapy for advanced lung, head and neck, bladder, ovarian, and uterine cancers before (Feb 1 2022–Feb 9 2023) or during (Feb 10 2023–Jan 31 2024) the platinum shortage. We calculated unadjusted proportions of patients initiating any platinum and each platinum type among all 1L treatment initiators before and during the shortage as well as absolute differences. Adjusted odds ratios for factors associated with platinum use were estimated with multivariable logistic regression. An adjusted hazard ratio (HR) for mortality in patients initiating treatment during compared to before the shortage was estimated using Cox regression.
Results
Among all 1L treatment initiators (n=11430) the unadjusted proportion receiving any platinum was 69.3% before and 65.7% during the shortage, a 3.6% (95% CI: −5.2, −1.8) absolute reduction in platinum use. There was no disproportionate change in platinum use by race, ethnicity, socioeconomic status, insurance, academic vs. community practice, or region. There was no difference in mortality before vs. during the shortage (HR 0.99; 95% CI 0.92–1.07). Table: 1548P
1L therapy | Before shortage, % (n=6521) | During shortage, % (n=4909) | Difference, % (95% CI) |
Any platinum | 69.3 | 65.7 | −3.6 (−5.3, −1.8) |
Cisplatin | 5.9 | 6.4 | +0.5 (−0.4, 1.4) |
Carboplatin | 63.4 | 59.4 | −4.1 (−5.9, −2.3) |
Conclusions
In this large U.S. cohort, during the shortage we observed a modest absolute decrease in platinum prescribing (∼4%) and no difference in mortality. Cisplatin was likely substituted for carboplatin for some patients. Understanding the role of mitigation strategies, such as alternative treatment choices proposed by oncologic societies, will offer important policy insight for future crises.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Institutes of Health, Clinical Cancer Epidemiology T32 CA009679.
Disclosure
R. Hubbard: Financial Interests, Personal, Funding: Johnson & Johnson, United States Department of Veterans Affairs. L. Sun: Financial Interests, Personal, Advisory Board: Sanofi Genzyme, Regeneron, GenMab, Seagen; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Institutional, Local PI: Blueprint, Seagen, IO Biotech, Erasca. R.B. Parikh: Financial Interests, Personal, Stocks/Shares: GNS Healthcare, Onc.AI; Financial Interests, Personal, Speaker, Consultant, Advisor: Cancer Study Group; Financial Interests, Personal, Licencing Fees: Medscape; Financial Interests, Personal, Speaker, Consultant, Advisor, travel reimbursement: Flatiron Health, Conquer Cancer Foundation. L.P. Martin: Financial Interests, Personal, Speaker, Consultant, Advisor: Elucida Oncology, Inc, Sutro Biopharma; Financial Interests, Personal, Other: Immunogen, Inc. R. Mamtani: Financial Interests, Personal, Advisory Board: BMS, Astellas/Seagen, Merck, King & Spalding; Financial Interests, Institutional, Research Grant: Astellas; Financial Interests, Institutional, Funding: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10